PMC:7205724 / 2521-2812
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
98 | 123-131 | Species | denotes | patients | Tax:9606 |
99 | 169-177 | Species | denotes | patients | Tax:9606 |
100 | 145-164 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
102 | 72-80 | Disease | denotes | COVID-19 | MESH:C000657245 |
103 | 236-241 | Disease | denotes | death | MESH:D003643 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T24 | 72-80 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T13 | 0-1 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T14 | 261-266 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T15 | 267-271 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T10 | 145-164 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T11 | 145-154 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T12 | 155-164 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T4 | 261-266 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T8 | 145-164 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T26 | 72-80 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T27 | 0-291 | Sentence | denotes | A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
102 | 72-80 | Disease | denotes | COVID-19 | MESH:C000657245 |
98 | 123-131 | Species | denotes | patients | Tax:9606 |
100 | 145-164 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
99 | 169-177 | Species | denotes | patients | Tax:9606 |
103 | 236-241 | Disease | denotes | death | MESH:D003643 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T394 | 0-1 | DT | denotes | A |
T395 | 2-12 | VBN | denotes | randomized |
T396 | 13-23 | VBN | denotes | controlled |
T397 | 24-29 | NN | denotes | trial |
T398 | 30-32 | IN | denotes | of |
T399 | 33-36 | CD | denotes | 199 |
T400 | 37-49 | VBN | denotes | hospitalized |
T401 | 50-56 | NNS | denotes | adults |
T402 | 57-61 | IN | denotes | with |
T403 | 62-71 | VBN | denotes | confirmed |
T404 | 72-80 | NN | denotes | COVID-19 |
T405 | 81-93 | VBD | denotes | demonstrated |
T406 | 94-96 | DT | denotes | no |
T407 | 97-103 | JJ | denotes | actual |
T408 | 104-114 | NN | denotes | difference |
T409 | 115-122 | IN | denotes | between |
T410 | 123-131 | NNS | denotes | patients |
T411 | 132-135 | WP | denotes | who |
T412 | 136-144 | VBD | denotes | received |
T413 | 145-164 | NN | denotes | lopinavir-ritonavir |
T414 | 165-168 | CC | denotes | and |
T415 | 169-177 | NNS | denotes | patients |
T416 | 178-181 | WP | denotes | who |
T417 | 182-190 | VBD | denotes | received |
T418 | 191-199 | JJ | denotes | standard |
T419 | 200-204 | NN | denotes | care |
T420 | 205-210 | RB | denotes | alone |
T421 | 211-213 | IN | denotes | in |
T422 | 214-222 | JJ | denotes | clinical |
T423 | 223-234 | NN | denotes | improvement |
T424 | 234-235 | -COMMA- | denotes | , |
T425 | 236-241 | NN | denotes | death |
T426 | 242-246 | NN | denotes | rate |
T427 | 246-247 | -COMMA- | denotes | , |
T428 | 248-251 | CC | denotes | and |
T429 | 252-260 | JJ | denotes | positive |
T430 | 261-266 | NN | denotes | virus |
T431 | 267-271 | NN | denotes | test |
T432 | 272-276 | NN | denotes | rate |
T433 | 277-279 | IN | denotes | at |
T434 | 280-283 | NN | denotes | day |
T435 | 284-286 | CD | denotes | 28 |
T436 | 287-288 | -LRB- | denotes | [ |
T437 | 288-289 | CD | denotes | 1 |
T438 | 289-290 | -RRB- | denotes | ] |
R393 | T397 | T394 | arg1Of | trial,A |
R394 | T397 | T395 | arg2Of | trial,randomized |
R395 | T397 | T396 | arg2Of | trial,controlled |
R396 | T397 | T398 | arg1Of | trial,of |
R397 | T401 | T398 | arg2Of | adults,of |
R398 | T401 | T399 | arg1Of | adults,199 |
R399 | T401 | T400 | arg2Of | adults,hospitalized |
R400 | T401 | T402 | arg1Of | adults,with |
R401 | T404 | T402 | arg2Of | COVID-19,with |
R402 | T404 | T403 | arg2Of | COVID-19,confirmed |
R403 | T397 | T405 | arg1Of | trial,demonstrated |
R404 | T408 | T405 | arg2Of | difference,demonstrated |
R405 | T408 | T406 | arg1Of | difference,no |
R406 | T408 | T407 | arg1Of | difference,actual |
R407 | T408 | T409 | arg1Of | difference,between |
R408 | T410 | T409 | arg2Of | patients,between |
R409 | T410 | T411 | arg1Of | patients,who |
R410 | T410 | T412 | arg1Of | patients,received |
R411 | T414 | T412 | arg2Of | and,received |
R412 | T413 | T414 | arg1Of | lopinavir-ritonavir,and |
R413 | T415 | T414 | arg2Of | patients,and |
R414 | T410 | T416 | arg1Of | patients,who |
R415 | T410 | T417 | arg1Of | patients,received |
R416 | T419 | T417 | arg2Of | care,received |
R417 | T419 | T418 | arg1Of | care,standard |
R418 | T419 | T420 | arg1Of | care,alone |
R419 | T417 | T421 | arg1Of | received,in |
R420 | T428 | T421 | arg2Of | and,in |
R421 | T423 | T422 | arg1Of | improvement,clinical |
R422 | T423 | T424 | arg1Of | improvement,"," |
R423 | T426 | T424 | arg2Of | rate,"," |
R424 | T426 | T425 | arg1Of | rate,death |
R425 | T428 | T427 | arg1Of | and,"," |
R426 | T424 | T428 | arg1Of | ",",and |
R427 | T432 | T428 | arg2Of | rate,and |
R428 | T432 | T429 | arg1Of | rate,positive |
R429 | T432 | T430 | arg1Of | rate,virus |
R430 | T432 | T431 | arg1Of | rate,test |
R431 | T432 | T433 | arg1Of | rate,at |
R432 | T434 | T433 | arg2Of | day,at |
R433 | T434 | T435 | arg1Of | day,28 |
R434 | T417 | T436 | arg1Of | received,[ |
R435 | T437 | T436 | arg2Of | 1,[ |
R436 | T438 | T436 | arg3Of | ],[ |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 236-241 | http://purl.obolibrary.org/obo/GO_0016265 | denotes | death |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T24 | 72-80 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T27 | 0-291 | Sentence | denotes | A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. |